SP Tulsian of sptulsian.com advises to remain invested in Aurobindo Pharma. "Look for current year results because Q1 numbers were good with topline of Rs 1,700 crore, EBITDA of Rs 310 crore," he reasons.
first published: Oct 1, 2013 03:36 pm
A collection of the most-viewed Moneycontrol videos.
The Lawyer Renting in a 120-year-old building in South Mumbai | The Tenant
Nifty On Track To End Week Above 25,500 As Bank & Metal Stocks Lead Rebound| Closing Bell Live
Can Nifty Stage A Friday Fightback After Hitting 3-Week Low? Pine Labs IPO Opens | Opening Bell Live
Nifty Stays Below 25,600 Amid Expiry-Led Volatility; Grasim, Hindalco In Focus| Closing Bell Live
